Dr. Cowan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
617 Eastlake Ave E
Seattle, WA 98109Phone+1 206-606-7348Fax+1 206-606-1043
Summary
- As an associate professor of medicine in the Div. of Medical Oncology at the University of Washington School of Medicine, my focus is in plasma cell disorders, specifically, MM and AL amyloidosis. I am involved in a variety of clinical research projects, both retrospective and prospective studies. I have a special interest in multiple myeloma and AL amyloidosis.
My clinical and research focus is on immunotherapy for MM, including CAR T cells; health services research in MM, and health informatics.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2012 - 2015
Boston University Medical CenterResidency, Internal Medicine, 2009 - 2011- Boston University Medical CenterInternship, Internal Medicine, 2008 - 2009
- University of Washington School of MedicineClass of 2008
Certifications & Licensure
WA State Medical License 2017 - 2025
AK State Medical License 2022 - 2024
MA State Medical License 2011 - 2013- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Start of enrollment: 2016 Aug 29
- A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma Start of enrollment: 2017 Nov 07
- A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2018 Apr 02
- Join now to see all
Publications & Presentations
PubMed
- 5 citationsProlonged Lenalidomide Therapy Does Not Impact Autologous Peripheral Blood Stem Cell Mobilization and Collection in Multiple Myeloma Patients: A Single-Center Retrospe...Andrew J. Cowan, Philip A. Stevenson, Damian J. Green, Sherilyn A. Tuazon, Edward N. Libby
Transplantation and Cellular Therapy. 2021-04-22 - 111 citationsFactors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignanciesJordan Gauthier, Evandro D. Bezerra, Alexandre V. Hirayama, Salvatore Fiorenza, Alyssa Sheih
Blood. 2021-01-21 - 30 citationsAnakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.Nicolas Gazeau, Emily C Liang, Qian Vicky Wu, Jenna M Voutsinas, Pere Barba
Transplantation and Cellular Therapy. 2023-07-01
Abstracts/Posters
- A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in C...Andrew J. Cowan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma SecretaseAndrew J. Cowan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Re...Andrew J. Cowan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Pembrolizumab in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Beyond BCMA-Directed CAR T-cell TherapyJune 21st, 2024- Clinical Challenges: Quadruplet Therapy in Multiple MyelomaJune 1st, 2021
Fred Hutch at ASH: Latest CAR T Data – BCMA, CD19, CD20 – plus New Insights on Transplantation, Gene Therapy – and MoreNovember 21st, 2019
Grant Support
- T32 Oncology Training GrantNIH2014–2015
Committees
- Reviewer, Scientific Review Committee, FHCRC 2016 - Present
Professional Memberships
- Member
- Fellow
External Links
- HemOnc.orghttp://hemonc.org
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
